| About Us |
| News & Events |
| Research |
| Publications |
| Affiliates |
| Cores |
 Biomolecule Production |
| High-throughput Screening |
| Live-cell Imaging |
| Microbiology and Animal Resources |
| Other Resources |
| Confocal Microscope |
| FACS |
| Mass Spectrometry |
| NMR |
| RNAi |
| NIAID/NIH Research |
| Useful Links |
| Contact Information |
| News & Events Archives |
| Copyright © 2009 by the President and Fellows of Harvard College |
Issue Date: April 15, 2009
Application Deadline: May 6, 2009
Download detailed instructions for the NERCE ARRA RFP here
The NERCE is eligible to receive support from the recently signed American Recovery and Reinvestment Act (ARRA). All areas of investigation that are outlined in RFA AI-08-002 are eligible for support with these funds, including proof-of-principle work, product-oriented studies, and basic research. The proposed research should be on NIAID category A-C agents or emerging and re emerging infectious diseases (http://www3.niaid.nih.gov/topics/emerging/list.html).
To qualify for support through the ARRA, projects must be exceptionally innovative. The research must demonstrate that it is of high risk but has the potential for high payoff if successful. It is expected that while these “out of the box” projects entail greater than the usual degree of scientific risk, they hold the potential for delivering transformational results or paradigm shifts. While the funding for these projects will terminate no more than two years after the award, it is expected that many of them will be able to continue with support from other sources.
Principal Investigators must be an employee of an academic, private, public, or corporate entity within Region I (CT, ME, MA, NH, RI, or VT). Collaborators may reside outside Region I. Foreign components are not allowed. Previous experience in the fields of biodefense or emerging infectious diseases is not required, and there is no requirement that the proposed research align with the thematic goals of NERCE. Proposals that were previously included in applications in response to RFA AI-08-002 are not eligible, and existing RCE projects may not be supplemented. Minorities, women and individuals with disabilities are encouraged to apply.
A project should request a minimum of $200,000 in direct costs per year for 1-2 years. All funds must be spent by the end of the award period. No clinical trials will be supported, and any involvement of human subjects must not entail more than minimal risk.